Philip Suh, MD
General Practice · Honolulu, HINPI 1518934009
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $211,562 of the $298,878 with a category attached, or 70.8%. 53 manufacturers reported payments, led by Amgen at 34.0% of the total. Reporting peaked in 2019 at $108,987 and has fallen 57.5% since, to $46,341 in 2025. Among general practice clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,956 payments — averaging $101.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$102K
- Novo Nordisk$33K
- AstraZeneca$32K
- Amarin Pharma, Inc.$30K
- AbbVie$26K
- Johnson & Johnson$24K
- plus $52K from 47 others
What the payments were for
- Consulting fees$8,5213%
- Speaking & faculty fees$211,56271%
- Travel & lodging$23,8238%
- Food & beverage$54,60218%
- Education$3700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$298,878 in reported general payments places this provider in the 95th percentile of 650 general practice providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 74 | $95,968 |
| ProliaDenosumab | 41 | $71,653 |
| VascepaIcosapent Ethyl | 75 | $56,453 |
| JanuviaSitagliptin Phosphate | 35 | $46,302 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 56 | $41,857 |
| InvokanaCanagliflozin | 27 | $35,738 |
| OzempicSemaglutide | 27 | $35,548 |
| MounjaroTirzepatide | 27 | $35,035 |
| RybelsusSemaglutide | 20 | $32,823 |
| TradjentaLinagliptin | 15 | $21,602 |
| Repatha SureclickEvolocumab | 17 | $12,679 |
| LivaloPitavastatin Calcium | 11 | $9,786 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $9,629 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,437 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 42 | $4,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $3,117 | $117,57089 claims |
| AmgenProlia | $101,597 | $71,65341 claims |
| Novo NordiskOzempic, Rybelsus | $33,325 | $68,37147 claims |
| MerckJanuvia | $1,078 | $46,30235 claims |
| AstraZenecaBreztri Aerosphere | $31,545 | $41,85756 claims |
| Johnson & JohnsonInvokana | $24,305 | $35,73827 claims |
| Lilly USA, LLCMounjaro | $3,025 | $35,03527 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $1,220 | $9,78611 claims |
| GSKTrelegy Ellipta | $3,100 | $9,62913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 650 general practice providers in Hawaii.
Other general practice in Honolulu
- Kent HironakaHonolulu$94K
- Jason AkoHonolulu$81K
- Wynn OkudaHonolulu$60K
- Russell TacataHonolulu$22K
- Eugene AzumaHonolulu$14K
- Blake KitamuraHonolulu$11K
- Lance TeramotoHonolulu$8K
- Kyrell WrightHonolulu$7K
- Ann HashitateHonolulu$7K
- William SiciliaHonolulu$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.